First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong

Journal of Travel Medicine

Volumn 23, Issue 4, 2016, Pages

  Leung, Wai Shing ^a   Chan, Man Chun ^a   Chik, Shiu Hong ^a   Tsang, Tak Yin ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Hong Kong; Viscerotropic disease; Yellow fever vaccination

Indexed keywords

C REACTIVE PROTEIN; INFUSION FLUID; PARACETAMOL; YELLOW FEVER VACCINE;

AGED; ARTICLE; CASE REPORT; CLINICAL ARTICLE; CONCENTRATION LOSS; CONFUSION; FEVER; HEADACHE; HONG KONG; HUMAN; JAUNDICE; LETHARGY; LOSS OF APPETITE; MALAISE; MALE; MYALGIA; REAL TIME POLYMERASE CHAIN REACTION; RESTLESSNESS; VACCINATION REACTION; VISCEROTROPIC DISEASE; YELLOW FEVER; ADVERSE EFFECTS; PRACTICE GUIDELINE; TRAVEL; VACCINATION; WORLD HEALTH ORGANIZATION;

AGED; HONG KONG; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; TRAVEL; VACCINATION; WORLD HEALTH ORGANIZATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84991663077     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1093/jtm/taw020     Document Type: Article

References (13)

1. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1:11-20
2. Staples JE, Gershman M, Foscher M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep 2010; 59:1-27
3. World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper June 2013. Wkly Epidemiol Rec 2013; 88:269-84
4. Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 2011; 11:622-32
5. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012; 11:427-48
6. Cottin P, NiedrigM, Domingo C. Safety profile of the yellow fever vaccine StamarilVR: a 17-year review. Expert Rev Vaccines 2013; 12:1351-68
7. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30:5038-58
8. Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 2014; 32:5769-75
9. Monath TP. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg 2010; 82:919-21
10. Rafferty El, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine 2013; 31:5798-805
11. Centers for Disease Control and Prevention. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Yellow Fever Vaccine Booster Doses. http:// www.cdc.gov/vaccines/acip/recs/grade/yf-vac-boost.html
12. Thomas RE, Spragins W, Lorenzetti DL. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria? Vaccine 2013; 31:6201-9
13. World Tourism Organization. UNWTO Tourism Highlights, 2015 Edition. http://www.e-unwto.org/doi/pdf/10.18111/9789284416899 (5 April 2016, date last accessed)